Results 291 to 300 of about 17,219,459 (310)

LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity

Cell
Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined nivolumab (anti-PD-1) and relatlimab (anti-LAG-3) treatment, the first in its class to ...
Lawrence P. Andrews, Samuel C. Butler, Jian Cui, Anthony R. Cillo, Carly Cardello, Chang Liu, Erin A. Brunazzi, Andrew Baessler, Bingxian Xie, S. Kunning, S. Ngiow, Y. J. Huang, Sasikanth Manne, Arlene H. Sharpe, Greg M. Delgoffe, E. Wherry, John M. Kirkwood, T. Bruno, C. Workman, D. A. Vignali   +19 more
semanticscholar   +1 more source

LAG-3 overexpression in pediatric Hodgkin lymphoma.

Journal of Clinical Oncology, 2020
10531 Background: The role of the PD-1/PD-L1 axis in Hodgkin Lymphoma (HL) has led to FDA approval for use of inhibitors in chemotherapy-refractory HL. Numerous additional immune checkpoints may be useful targets, but have not yet been evaluated in HL.
Scott Moerdler, Michelle Ewart, Mou Peng, Xingxing Zang, Peter D. Cole   +4 more
openaire   +1 more source

Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity

Cell
Relatlimab (rela; anti-LAG-3) plus nivolumab (nivo; anti-PD-1) is safe and effective for treatment of advanced melanoma. We designed a trial (NCT03743766) where advanced melanoma patients received rela, nivo, or rela+nivo to interrogate the immunologic ...
Anthony R. Cillo, Carly Cardello, Feng Shan, Lilit Karapetyan, S. Kunning, C. Sander, Elizabeth Rush, A. Karunamurthy, Ryan C. Massa, Anjali Rohatgi, C. Workman, John M. Kirkwood, T. Bruno, D. A. Vignali   +13 more
semanticscholar   +1 more source

Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function

Proceedings of the National Academy of Sciences of the United States of America
Significance T cell activation is tightly regulated by activating and inhibitory receptors. One of these inhibitory receptors, Lymphocyte activation gene-3 (LAG-3), is currently being targeted in oncology clinical trials to enhance anti-tumor immunity ...
John L Silberstein, Jasper Du, K. Chan, Jessica A Frank, Irimpan I. Mathews, Yong Bin Kim, Jia You, Qiao Lu, Jia Liu, Elliot A Philips, Phillip Liu, Eric Rao, Daniel Fernández, Grayson E. Rodriguez, Xiang-Peng Kong, Jun Wang, Jennifer R. Cochran   +16 more
semanticscholar   +1 more source

Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways

Hepatoma Research
Hepatocellular carcinoma (HCC) stands as a primary malignant liver tumor characterized by chronic inflammation and complex alterations within the tumor microenvironment (TME).
Konstantinos Arvanitakis, Stavros P. Papadakos, Georgios Vakadaris, Elena Chatzikalil, I. Stergiou, Georgios Kalopitas, Stamatios Theocharis, Georgios S. Germanidis   +7 more
semanticscholar   +1 more source

PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets

EMBO Molecular Medicine
Many cancer patients do not benefit from PD-L1/PD-1 blockade immunotherapies. PD-1 and LAG-3 co-upregulation in T-cells is one of the major mechanisms of resistance by establishing a highly dysfunctional state in T-cells.
L. Chocarro, E. Blanco, L. Fernández-Rubio, M. Garnica, M. Zuazo, Maria Jesus Garcia, A. Bocanegra, M. Echaide, C. Johnston, Carolyn J Edwards, James Legg, Andrew J Pierce, H. Arasanz, G. Fernández-Hinojal, Ruth Vera, K. Ausín, Enrique Santamaria, J. Fernández-Irigoyen, G. Kochan, D. Escors   +19 more
semanticscholar   +1 more source

LAG-3 antagonists by cancer treatment: a patent review

Expert Opinion on Therapeutic Patents, 2019
Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer.
Martin Perez-Santos, Maricruz Anaya-Ruiz, Jorge Cebada, Cindy Bandala, Gerardo Landeta, Patricia Martínez-Morales, Nemesio Villa-Ruano   +6 more
openaire   +2 more sources

Crystal structure of the human LAG-3-HLA-DR1-peptide complex.

Science immunology
T cell activity is governed by T cell receptor (TCR) signaling and constrained by immune checkpoint molecules, including programmed cell death protein 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and lymphocyte activation gene 3 (LAG-3)
J. Petersen, Carmen Llerena, Bagher Golzarroshan, Camilla Faoro, F. Triebel, Jamie Rossjohn   +5 more
semanticscholar   +1 more source

Anti-LAG-3 boosts CD8 T cell effector function

Cell
LAG-3 is the third immune checkpoint pathway successfully targeted for cancer therapy. Although ineffective as a monotherapy, combination of LAG-3 and PD-1 blockade improves survival from advanced melanoma. In this issue of Cell, two studies in mice and a human clinical trial provide insights on LAG-3 in immune regulation.
Courtney T, Kureshi, Michael, Dougan, Stephanie K, Dougan   +2 more
openaire   +2 more sources

The CD4-like molecule LAG-3, biology and therapeutic applications

Expert Opinion on Therapeutic Targets, 2010
Promising immunotherapeutic agents targeting co-stimulatory pathways are currently being tested in clinical trials. One player in this array of regulatory pathways is the LAG-3/MHC class II axis. The lymphocyte activation gene-3 (LAG-3) is a negative co-stimulatory receptor that modulates T cell homeostasis, proliferation and activation.
Sophie, Sierro, Pedro, Romero, Daniel E, Speiser   +2 more
openaire   +2 more sources